Integrins mediate the adhesion of cells to each other and to the extracellular matrix during development, immunity, metastasis, thrombosis and wound healing. Molecular defects in either the -or -subunit can disrupt integrin synthesis, assembly, and/or binding to adhesive ligands. This is exemplified by the bleeding disorder, Glanzmann thrombasthenia (GT), where abnormalities of the platelet-specific integrin, IIb 3, prevent platelet aggregation following vascular injury. We previously utilized a retrovirus vector containing a cDNA cassette encoding human integrin 3 to restore integrin IIb 3 on the surface of megakaryocytes derived from peripheral blood stem cells of GT patients. In the present study, bone marrow from 3-deficient (-/-) mice was transduced with the 3-cassette to investigate whether the platelet progeny could establish hemostasis in vivo. A lentivirus transfer vector equipped with the human IIb gene promoter confined transgene expression to the platelet lineage. Human 3 formed a stable complex with murine IIb, effectively restoring platelet function. Mice expressing significant levels of IIb 3 on circulating platelets exhibited improved bleeding times. Intravenous immunoglobulin effectively diminished platelet clearance in animals that developed an antibody response to IIb 3. These results indicate the feasibility for targeting platelets with genetic therapies for better management of patients with inherited bleeding disorders.
Introduction
Several hundred different proteins orchestrate the adhesion of platelets to the exposed extracellular matrices, signal transduction, aggregation, and clot retraction leading to the formation of a platelet-plug that helps stop the flow of blood from a wound site. At least five members of the evolutionarily conserved integrin family of adhesion receptors are present on platelets to aid in these processes including 2 1, 5 1, 6 1, v 3, and IIb 3. 1, 2 The molecular structure was recently solved for one integrin, v 3, 3 which directs binding of platelets and a variety of other cell types to vitronectin. Unlike v 3, integrin IIb 3 is expressed exclusively on megakaryocytes and platelets (N80,000 copies per platelet) 4 due to the presence of promoter regulatory elements that direct high level, selective transcription of the IIb gene early in megakaryocytopoiesis. 5 IIb 3 mediates the interaction of activated platelets with multiple adhesive ligands, including fibrinogen, von Willebrand factor (VWF), fibronectin, thrombospondin and collagen. 2 Upon activation, IIb 3 changes its shape to bind its ligand with high affinity for effective platelet aggregation and retraction of a fibrin clot to seal a wound. 6, 7 Glanzmann Thrombasthenia (GT) is a rare autosomal-recessive bleeding disorder resulting from genetic defects of either integrin IIb or 3 that disrupt subunit synthesis, receptor assembly, and/or function thus preventing IIb 3 from binding ligands essential for proper platelet aggregation. 8 More than 100 distinct genetic defects have been characterized for GT, occurring with even distribution in both genes. 9 The diagnosis of thrombasthenia, meaning "weak platelets," is based on the demonstration of normal platelet levels, but abnormal platelet aggregation and clot retraction in For personal use only. on April 15, 2017. by guest www.bloodjournal.org From response to physiological agonists ADP, epinephrine and thrombin. 10 ,11 3(-/-) mice exhibit a condition that is essentially identical to the phenotype for GT in humans where defective platelet function leads to prolonged bleeding. 12 Interestingly, 3(-/-) mice also display abnormalities in placental development, osteosclerosis, 13 and increased tumor hypervascularization 14 and growth 15 ; thus underscoring a vital role for v 3 in those processes. 2 The current study was designed to improve our understanding relevant to the use of hematopoietic stem cells for gene therapy of hemorrhagic disorders. Information acquired from this work should be particularly useful for developing strategies to alleviate uncontrolled bleeding due to inherited platelet defects. Three issues were addressed: 1) Can mutant bone marrow stem cells be given adequate genetic information to allow megakaryocyte progeny to synthesize a transgene product that will help newly formed platelets to participate in normal hemostasis? 2) Will the product be maintained as a platelet-specific protein at therapeutic levels for a reasonable period of time? and 3) Can the product be tolerated by the immune system or become a target for B-and T-cell-mediated immunity resulting in the premature destruction and clearing of the genetically-altered megakaryocytes and platelets? The outcome from this study demonstrates the feasibility of platelet-specific gene therapy, and paves the way for future studies in patients suffering from inherited-bleeding disorders.
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Materials and methods
Antibodies. Biotinylated-antibody to murine v (CD51), phycoerythrin (PE)-conjugated antibody specific for human 3 (CD61), PE-anti-murine TER-119 and FITC-conjugated antibody to murine proteins: IIb (CD41), CD45R/B220, Thy1.2 (CD90.2), Ly-6G,C, MAC-1 and isotype standards (PE-IgG, FITC-IgG) were from BD Biosciences (San Jose, CA). FITC-anti-human 3, a polyclonal antibody to murine VWF and the isotype control were from Dako (Carpinteria, CA). An antibody (7E3) 16 specific for the complex of human IIb 3 and v 3 was a gift from B. Coller (Rockefeller University, New York, NY). An antibody to an epitope exposed on the high affinity conformation of human 3 (D3) 17 was a gift from L. Jennings (University of Tennessee, Memphis, TN). An antibody to human IIb 3 complex (AP2) 18 was from our Hybridoma Core Laboratory. PE-anti-murine IIb 3 activated complex specific (Jon/A) and FITC-rabbit anti-murine fibrinogen antibodies were from Emfret Analytics (Würzburg, Germany). An antibody to murine glycoprotein (GP)Ib (PE-p0p4) 19 was a gift from B. Nieswandt (University of Würzburg, Germany). FITC-F(ab') 2 goat anti-murine IgG Fc was from Jackson ImmunoResearch (West Grove, PA) A PE-anti-biotin antibody was from Miltenyi Biotec (Gladbach, Germany).
Lentivirus. A fragment of the human IIb gene promoter beginning at nucleotide -889
was previously used to drive transcription of cDNA encoding human 3 (gift of P.
Newman, Blood Research Institute, Milwaukee, WI) 20 within the Maloney Murine Leukemia oncoretrovirus (MuLV) vector, p-889PlA2 3 as described. 21, 22 To construct lentivirus plasmid p 3-WPTS, the human IIb gene promoter driven 3 cDNA cassette For personal use only. on April 15, 2017. by guest www.bloodjournal.org From was excised from p-889PlA2 3 and subcloned into an HIV type-1 construct, pWPTS-GFP (gift of D. Trono, University of Geneva, Switzerland), 23 replacing the elongation factor-1 promoter/GFP cDNA cassette. A lentivirus, p-889GFPII-WPTS, was also constructed for platelet-specific expression of a reporter gene, green fluorescent protein (GFP). The human IIb gene promoter for GFP was amplified by PCR from genomic DNA isolated from the human promegakaryocytic cell line, Dami, using nucleotide -889 to -872 (bold type) sense primer of IIb (5'-TTACGCGTCGACAGATCTCCTTGCCACCTAGACC-3') and antisense primer (5'-CGTCTTCCATGGTCCTTCTTCCACAACC-3') encoding an Nco I restriction site and nucleotides +30 to +15 of IIb and cloned into pGL3 (Promega, Madison, WI). The IIb gene promoter sequence was confirmed by nucleotide analysis and the PCR product was excised from pGL3 and cDNA encoding a human ranilla GFP gene variant was excised from phrGFPII-1 (Stratagene, La Jolla, CA) and subcloned into (p)WPTS-GFP replacing the elongation factor-1 promoter/GFP cDNA cassette.
Recombinant lentivirus was generated from HEK 293T cells (6 x 10 6 cells/100 mm plate) co-transfected with calcium phosphate precipitation of three plasmids: p 3-WPTS or p-889GFPII-WPTS, and a construct expressing the HIV-1 gag/pol, tat, and rev genes required for efficient LV production, pCMV R8.91 (gift of D. Trono), 24 and a plasmid expressing the vesicular stomatitis virus envelope glycoprotein (G), pCI-VSV-G (gift of J. Olsen, University of North Carolina, Chapel Hill, NC) at 15:15:7.5 µg/plate. Virus was collected and concentrated 500-fold by low-speed centrifugation and stocks were stored frozen at -80 o C until utilized as previously described. 21 Virus titer was determined by real-time quantitative reverse transcriptase-polymerase chain reaction measuring For personal use only. on April 15, 2017. by guest www.bloodjournal.org From copies of proviral DNA integrated into the genome of circulating murine mononuclear cells as recently described. 25 Replication-competent virions were confirmed absent from viral stocks by using extended marker rescue assays. 22
Murine Bone Marrow Isolation, Transduction and Transplantation. Bone marrow was isolated from 3(-/-) 12 or 3(+/+) mice and Ficoll-purified mononuclear cells were transduced at a multiplicity of infection (MOI) equal to five 3 virions per 3(-/-) cell or three -889GFPII virions per 3(+/+) cell over a twenty-four hour period as previously described. 26 A dose of 9.0 x 10 6 cells was transplanted by tail vein injection (500 µl/mouse) into each recipient (6-8 weeks age) conditioned with a lethal dose of 1,100 cGy total body irradiation with a cesium irradiator (Shepherd Mark I, J.L. Shepherd, San Fernando, CA). Results shown with six mice in this study reflect a range of observations recorded with 21 mice that received a primary transplant of bone marrow transduced with a lentivirus construct containing the IIb gene promoter driven 3 cDNA cassette. Fourteen mice were initially transplanted with the IIb gene promoter driven 3 cDNA cassette within the MuLV oncoretrovirus backbone. 22 3-transgene expression persisted for only 10-15 weeks post-transplant (likely resulting from inactivation of MuLV); 27 and therefore, the lentivirus backbone was substituted for MuLV to transfer of the 3 cassette into bone marrow transplanted into 21 additional mice to obtain more stable transgene expression. 24 Gene expression and function was also examined with platelets collected from mice that received 3-lentivector transduced bone marrow from one donor (mouse A) as a second (2 mice) or third (4 mice) generation transplant recipient. Animal studies complied with institutional guidelines Aggregation was monitored on a PAP-4 platelet aggregation profiler and analyzed with data interface software (BioData Corporation). Studies to measure inhibition of platelet aggregation were performed by pre-treating platelets with 7E3 for 30 minutes at 37 o C followed by the addition of fibrinogen and agonist as described above.
Pulmonary Thromboembolism Assay.
To determine if platelet function was restored in vivo, mice were intravenously injected with 0.35 mg/kg of platelet agonist, ADP (25 mg/ml), in Tyrode's buffer as previously described. 30 Circulating platelets levels were measured with an Animal Blood Counter (Oxford Science, Oxford, CT) one hour before and five minutes after ADP treatment. Each animal was sacrificed at 10 minutes postinjection. The lungs were removed and immersed in 10% neutral-buffered formalin, embedded in paraffin, and sections were prepared in our histology core facility with Gomori's trichrome stain to demonstrate differential staining of protein fibers (fibrotic tissue: muscle, collage fibers, fibrin clots) and erythrocytes. Lung sections were mounted on glass slides, examined with a light microscope (400x magnification) and photographed using a Kodak digital camera using Microscopy Documentation System 290 software.
Bleeding Time Assay. The tail bleeding time was defined as the time required for a stream of bleeding to end from a severed tip of a tail that was immersed in 0.9% isotonic saline at 37°C as previously described. 12 The average bleeding time was reported for 3(-/-,+/+) controls consisting of twenty mice per group. Tails were cauterized if bleeding proceeded beyond the experimental endpoint of 600 seconds.
Assay to Detect an Immune Response to IIb 3. Flow cytometry was used to
determine if murine plasma contained antibodies that recognized proteins on the surface of platelets from mice and humans (provided by B. Curtis, BloodCenter of Wisconsin). Platelets were washed and incubated with 1:10 diluted murine plasma and a FITC-conjugated F(ab') 2 goat anti-murine IgG Fc (1:100 diluted) and examined by flow cytometry as previously described. 31 An antibody to the human IIb 3 complex (AP2) was used as a positive control for human platelets and an antibody to murine GPIb was used as a positive control for recognition of mouse platelets. Buffer served as a negative control and buffer-diluted plasma from control mice served as an internal negative control. The ratio of antibody binding to platelets was determined by dividing the MFI of platelets with mouse (A) plasma by the MFI of platelets with control buffer as previously described. 31 
Results

Platelet-Specific Expression of Integrin 3.
To investigate the feasibility of gene therapy for correcting molecular defects in platelets, we targeted expression of the human integrin 3-subunit in megakaryocytes of 3(-/-) mice affected with GT. In Fig.1A , cDNA encoding human 3 was subcloned into a vector derived from an HIV type-1 lentivirus. 23 The enhancer/promoter of the viral 3'-long terminal repeat (LTR) was removed from this construct to allow the vector to self-inactivate (SIN) and the human IIb gene promoter was used to direct megakaryocyte-specific synthesis of 3.
This promoter binds (GATA and Ets) factors that mediate high-level gene transcription,
which is confined to megakaryocytes due to the presence of a repressor region that inhibits gene expression in other lineages. 5 indicting that murine platelets express integrin 3 primarily in complex with murine IIb (data not shown).
In Fig. 1D , we observed that an antibody (7E3) 16 specific for human integrin 3 in complex with IIb or v reacted only with normal human platelets and murine platelets expressing human 3 (panel 1), thus indicating that murine IIb formed a hybrid complex with human 3. Further studies suggest that the hybrid integrin complex can be induced to undergo a conformational change consistent with outside-in integrin signaling, since platelets from transplanted mice bound an antibody (D3) 17 that reacts specifically with an epitope exposed on the high affinity conformation of human 3 following treatment of platelets with a fibrinogen mimetic peptide containing Arg-Gly-Asp 
A lentivirus vector encoding GFP under the transcriptional control of the human IIb gene promoter was transduced into murine bone marrow and transplanted into
For personal use only. on April 15, 2017. by guest www.bloodjournal.org From lethally-irradiated 3(+/+) mice to determine if the human IIb gene promoter confined transgene expression to the murine platelet lineage ( Fig. 2A) . Flow cytometric analysis performed on platelets isolated from the peripheral blood of one mouse showed significant levels of GFP with an MFI equal to five times the level detected in platelets from an animal that did not receive a transplant of GFP-transduced marrow (row 1). In contrast, cells exhibiting the forward and side scattering properties of white (row 2) and red blood (row 3) cells failed to demonstrate measurable levels of GFP as evidenced by the overlapping fluorescent histograms of cells from the transplant recipient with the negative control suggesting that the human IIb promoter targeted transgene expression specifically to murine platelets.
To determine if human 3 was expressed exclusively on platelets, flow cytometric analysis was performed on whole blood isolated from 3(-/-) mice transplanted with 3transduced bone marrow (Fig. 2B) . Peripheral blood was collected from mouse D;
which had one of the highest expression levels of 3 on its platelets (previously shown in Fig.1B ). Blood cells were simultaneously stained with PE-and FITC-conjugated antibodies, one specific for human 3 (y-axis) and the other, a marker for a distinct murine cell type (x-axis). Approximately 500-2,500 positive events were collected for each lineage-specific marker. A cell type was considered to express human 3 if a significant percentage of cells simultaneously stained positive with both antibodies (upper right quadrant of each density plot). As expected, platelets from controls expressed murine IIb at different levels (identical to Fig. 1C) , while another plateletspecific marker, GPIb, as well as markers for all other cell lineages were expressed uniformly in control mice (column 1-7, rows 1-3) . Furthermore, the results showed that human 3 was not detected in association with the surface marker for any cell type from Fig.1) .
Platelets from mouse A failed to aggregate (-14%), whereas mice B (42%), C (46%) and D (52%) each showed restored aggregation in accord with their increasing levels of IIb 3 on platelets. Platelets from experimental mice also aggregated in the presence of murine fibrinogen (not shown). In addition, samples could be induced to aggregate with a single agonist (ADP) as well as using the cocktail of physiological agonists (not shown). When a mixture of platelets from mice E and F was pretreated with the complex-specific antibody, 7E3, we observed that agonist-induced platelet aggregation Fig. 3C) .
A tail bleeding time assay was used to test whether platelets were able to mediate in vivo aggregation and clot retraction necessary to seal a wound. As previously reported, 12 we also measured short bleeding times in normal 3(+/+) mice (N97 seconds, n=20) when a distal 3 mm segment of tail was removed and immersed in revealed that plasma from mouse A also bound to murine platelets expressing murine 3 at normal (+/+) and partial (+/-) levels as well as murine 3(-/-) platelets expressing human 3. However, plasma from mouse A did not react with platelets from a 3(-/-) mouse indicating that the antibody response in mouse A was specific for the IIb 3 complex and/or the individual integrin subunits.
Intravenous immunoglobulin (IVIG) has been used in people to attenuate an acquired immune response to integrin IIb 3. 35 Therefore, mouse A was treated with IVIG to investigate whether its immune response to the newly formed IIb 3 complex could be alleviated. Flow cytometric analysis detected an immediate reduction in the level of plasma Ig from mouse A that bound to human platelets following three injections of IVIG (0.5 mg/g) (Fig. 4C, black line) . As a result, there was also a marked rise in the level of IIb 3 expressed on platelets from mouse A (Fig. 4C, orange line) , which stabilized at 20 weeks post-transplant (9 weeks after IVIG). A platelet aggregation assay performed at 27 weeks post-transplant showed that function was also restored in platelets from mouse A (Fig. 4D) . 
Transgenic expression of IIb 3 was monitored in mice
Discussion
There are several megakaryocyte-specific gene promoters that could potentially direct transgene transcription including: members of the GPIb-V-IX complex, 36 IIb, 37 GPVI, 38 , c-mpl, 39 and platelet factor 4. 40 These promoters bind GATA-1, Ets (Fli-1) and FOG-1 factors that induce transcription in early-and mid-stages of megakaryocytopoiesis. 41, 42 When human CD34+ peripheral blood stem cells were transduced with a retrovirus construct controlled by an 889 nucleotide fragment of the human IIb promoter, we previously observed lineage-specific transgene expression of a reporter gene in cultured megakaryocytes of normal individuals, 21 and ex vivo correction of the GT phenotype following the expression of the human integrin 3-subunit in megakaryocytes derived from GT patients. 22 Since nucleotide sequence analysis revealed a high degree of homology between the gene promoters for human and murine IIb, 43 and recent studies demonstrated that the human promoter fragment could drive "speciesindependent" megakaryocyte-specific gene expression in transgenic mice, 44 Figs. 1   & 2) . Storage of fibrinogen was re-established when 3(-/-) platelets expressed human 3 (Fig. 1) . Interestingly, VWF was detected at 3-4 fold higher levels within platelets of 3(-/-) mice compared 3(+/-, +/+) controls. This parallels finding of a recent report For personal use only. on April 15, 2017. by guest www.bloodjournal.org From describing increased levels of another -granule protein, TGF-1, within 3(-/-) platelets. 45 As observed for fibrinogen, VWF levels returned closer to normal values when 3(-/-) platelets were induced to express human 3 (Fig. 1) . This indicates that modulation of IIb 3 receptor levels may directly or indirectly affect the storage of other platelet proteins, although the mechanism and its potential effect on hemostasis and whether this occurs in human GT patients require further study. IIb 3 was detected at subnormal levels on the surface of platelets from mice that received transplants of 3-transduced marrow (ranging from 6-12% of normal IIb 3 receptor density) ( Figs. 1   & 2) . This result is remarkable since most of these animals displayed restored platelet function (Fig. 3) . The hybrid IIb 3 complex appeared to play a direct role in the aggregation of activated platelets since monoclonal antibody, 7E3, 16 inhibited aggregation of 3-transduced murine platelets as occurs when 7E3 binds specifically to IIb 3 and v 3 causing reduced ligand recognition of normal human platelets. Results from bleeding time assays suggest that it is critical to obtain at least 7% of normal levels of integrin IIb 3 receptors per platelet to achieve effective wound healing in the 3(-/-) mouse since platelets with lower receptor levels were unable to control bleeding.
Future studies to improve gene therapy for GT will likely explore methods to increase platelet receptor levels by use of recently characterized distal regulatory elements shown to enhance the IIb promoter's fragments ability to drive high-level, megakaryocyte-specific transgene expression. 46 Intravenous immunoglobulin effectively diminished platelet clearance and led to restored platelet function in a mouse (A) that developed an antibody response to IIb 3
For personal use only. on April 15, 2017. by guest www.bloodjournal.org From (Fig. 4) . This issue is critical because human gene therapy for GT could lead to the formation of 1) inhibitory antibodies to IIb 3 that prevent platelet aggregation, and/or 2) an immune response that results in clearance of transduced platelets and thrombocytopenia as seen for GT patients that become refractory to transfused platelets from normal donors. 11 Integrin IIb 3 is a major antigen for allo-, auto-, and isoimmune-mediated thrombocytopenias, where antibody-coated or immune complexcoated platelets are destroyed prematurely by the reticuloendothelial system resulting in peripheral blood thrombocytopenia. 35 Patients with immune-mediated platelet clearance have been successfully treated with corticosteroids, intravenous immunoglobulin (IVIG), and splenectomy. 47 Therefore, it seemed reasonable to try to alleviate this condition in the experimental mice with one of these therapies. Following IVIG, plasma from mouse A showed an immediate drop in the level of Ig binding to platelets, which correlated with an increase in platelets expressing IIb 3 (Fig. 4) . This is consistent with results of IVIG use in humans, 48 and further suggests that this may be a useful model to investigate IVIG's mechanism of action. 49 Results from this study indicate the likelihood for platelets to deliver additional therapeutic agents to the site of a vascular injury for treatment of other platelet defects and more common bleeding disorders such as hemophilia, 26 (E) Platelets from the mouse described in section (D) were fixed and permeabilized to perform quantitative analysis with rabbit polyclonal antibodies to detect the intracellular storage of major ligands for IIb 3, fibrinogen and VWF. Panel 1, histogram shows that a non-reactive Alexa647-rabbit polyclonal antibody did not react with murine platelets expressing human 3 (shaded peak) nor did it stain platelets from 3(-/-,+/-,+/+) controls. A non-reactive FITC-Ig showed identical results (not shown). 
(B)
Aggregation was measured ex vivo following a 30 minute pretreatment of platelets at 37 o C with IIb 3 and v 3 complex specific antibody, 7E3 (known to inhibit platelet aggregation) 16 , followed by incubation of washed platelets with human fibrinogen and a cocktail of platelet activation agonist (ADP, epinephrine, and PAR4).
Shown is the aggregation profile of a mixture of platelets from 3-transduced marrow recipients E-F, which was increasingly inhibited with higher concentrations of 7E3 (0-50 ug/ml). This result represents the outcome of three separate experiments. Aggregation was not inhibited with non-specific mouse Ig. (A) Flow cytometric histograms showed that plasma from mice A and B contained Ig antibodies (shaded peak) that reacted with normal human platelets. Displayed is the relative fluorescence intensity of human platelets incubated with 1:10 diluted murine plasma and a FITC-conjugated F(ab') 2 goat anti-murine IgG Fc secondary antibody.
Platelets incubated with secondary antibody and dilution buffer served as a negative control, while a monoclonal antibody to the human IIb 3 complex (AP2) was used as a positive control. This result was observed four times using platelets from two separate human donors analyzed on two separate occasions.
As in panel A, fluorescence analysis showed that 1:10 diluted plasma from mouse A also reacted with platelets from normal 3(+/+), heterozygous 3(+/-) mice as well as platelets from another human 3-transduced transplant recipient (shaded peak). In striking contrast, plasma did not react with platelets isolated from a 3(-/-) mouse.
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(C) IVIG (0.5 mg/g body weight) was injected each day for three days into mouse A. 
